In August, Questcor Pharmaceuticals announced “a new strategy and business model for H.P. Acthar Gel(R).” Later that month you may have read my post (Abusing the orphan drug law to rip off customers), which explained how the company obtained orphan drug status for a product that had already been used for decades for […]
Continued Read ...
As reported extensively on the Health Business Blog (see here, here, here, here, here, here, and here ) Genentech has undergone a contentious period with the American Academy of Ophthalmology (AAO) and American Society of Retina Specialists (ASRS). Compounding pharmacies have been repackaging Avastin into small doses, which eye doctors then use in […]
Continued Read ...
Scientific research into alternative treatments and new drugs are commonly “doubled up” by the combination of looking at two alternatives simultaneously, and by “blinding” both patients and providers as to which patients are getting which of the alternatives.
This serves to minimize bias due to the “placebo effect”. If patients and providers knew […]
Continued Read ...
